Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Vetbiolix communicates on the final results of the proof-of-concept study of VBX-2000 in canine osteoarthritis

From Vetbiolix

By

November 27, 2024

Vetbiolix communicates on the final results of the proof-of-concept study of VBX-2000 in canine osteoarthritis

Vetbiolix communicates on the final results of the proof-of-concept study of VBX-2000 in canine osteoarthritis
Vetbiolix has announced final results from its proof-of-concept clinical study of VBX-2000 (piclidenoson) in dogs with osteoarthritis, demonstrating positive efficacy signals.

View original article on vetbiolix.com

Most Recent

Travis Kalanick’s robotics company raises $1.7B, led by a16z

Travis Kalanick’s robotics company raises $1.7B, led by a16z

Uber is also investing in Travis Kalanick's company Atoms, which has made gauzy claims about using industrial AI to modernize the world.

Jul 22, 2026

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

As Chinese AI models grow in capability and popularity among U.S. companies, the arguing over what should be done about them has reached a fever pitch.

Jul 22, 2026

Cascade raises $3.5M to help construction firms find and win projects

Cascade raises $3.5M to help construction firms find and win projects

a16z Speedrun, Ada Ventures, and Snowball VC have invested in Cascade's $3.5 million seed round.

Jul 22, 2026

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

We’ve compiled an overview of some of the top alternative browsers available today aiming to challenge Chrome and Safari.

Jul 22, 2026

Similar Posts

Vetbiolix completes a Series A fundraising of €4m and launches the European regulatory clinical development of its First-in-class drug candidates

Vetbiolix completes a Series A fundraising of €4m and launches the European regulatory clinical development of its First-in-class drug candidates

Dec 1, 2024

Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®

Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®

LongBio announced positive topline results from Phase II trial of LP-003 vs Xolair (omalizumab) in CSU. LP-003 demonstrated comprehensive clinical advantages with statistically superior outcomes in key efficacy endpoints. Presented as late-breaking poster at 2026 AAAAI.

Mar 1, 2026

Healx, an AI-enabled drug discovery platform for rare diseases, raises $47M

Healx, an AI-enabled drug discovery platform for rare diseases, raises $47M

The company also said it has received regulatory clearance to start Phase 2nclinical trials for a new drug in the U.S. later this year.

Aug 1, 2024

Robot guard dogs help Asylon raise a $26M Series B

Robot guard dogs help Asylon raise a $26M Series B

DroneDogs can be sent to places unsafe for humans or real dogs and can do tasks like dangerous chemical detection.

Jul 22, 2025

Most Recent

Travis Kalanick’s robotics company raises $1.7B, led by a16z

Travis Kalanick’s robotics company raises $1.7B, led by a16z

Uber is also investing in Travis Kalanick's company Atoms, which has made gauzy claims about using industrial AI to modernize the world.

Jul 22, 2026

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

Arcee, a US open source AI lab, says Chinese models are not inherently dangerous

As Chinese AI models grow in capability and popularity among U.S. companies, the arguing over what should be done about them has reached a fever pitch.

Jul 22, 2026

Cascade raises $3.5M to help construction firms find and win projects

Cascade raises $3.5M to help construction firms find and win projects

a16z Speedrun, Ada Ventures, and Snowball VC have invested in Cascade's $3.5 million seed round.

Jul 22, 2026

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

The browser wars aren’t about search anymore — here are the best alternatives to Chrome and Safari

We’ve compiled an overview of some of the top alternative browsers available today aiming to challenge Chrome and Safari.

Jul 22, 2026

Similar Posts

Vetbiolix completes a Series A fundraising of €4m and launches the European regulatory clinical development of its First-in-class drug candidates

Vetbiolix completes a Series A fundraising of €4m and launches the European regulatory clinical development of its First-in-class drug candidates

Dec 1, 2024

Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®

Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®

LongBio announced positive topline results from Phase II trial of LP-003 vs Xolair (omalizumab) in CSU. LP-003 demonstrated comprehensive clinical advantages with statistically superior outcomes in key efficacy endpoints. Presented as late-breaking poster at 2026 AAAAI.

Mar 1, 2026

Healx, an AI-enabled drug discovery platform for rare diseases, raises $47M

Healx, an AI-enabled drug discovery platform for rare diseases, raises $47M

The company also said it has received regulatory clearance to start Phase 2nclinical trials for a new drug in the U.S. later this year.

Aug 1, 2024

Robot guard dogs help Asylon raise a $26M Series B

Robot guard dogs help Asylon raise a $26M Series B

DroneDogs can be sent to places unsafe for humans or real dogs and can do tasks like dangerous chemical detection.

Jul 22, 2025